- Agilent Technologies has launched Agilent Advanced Therapeutics, a unified CDMO platform integrating manufacturing capabilities across the United States and Canada.
- The platform combines BIOVECTRA in Canada and Agilent’s Nucleic Acid Solutions operations in Colorado to provide end-to-end development and contract manufacturing services.
Agilent Technologies has launched Agilent Advanced Therapeutics, a unified contract development and manufacturing organization (CDMO) platform designed to integrate the company’s expanding manufacturing capabilities across the United States and Canada. The initiative brings together expertise in oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent active pharmaceutical ingredients, and cell line development.
The new platform combines the capabilities of BIOVECTRA in Canada with Agilent’s Nucleic Acid Solutions operations in Colorado. According to the company, the integrated structure enables it to offer scalable and customizable manufacturing services for pharmaceutical and biotechnology partners across multiple therapeutic modalities.
Agilent said the platform will provide customers with a single partner for development and manufacturing, covering activities from discovery and process development through to clinical and commercial-scale contract manufacturing.
“[It] strengthens our ability to support our customers and reinforces our long-term commitment to growth, investment, and leadership.”
Padraig McDonnell, President and CEO of Agilent Technologies
Agilent reported $6.95 billion in revenue in fiscal year 2025 and employs approximately 18,000 people worldwide. The company stated that the Advanced Therapeutics platform is intended to support the development and manufacturing of next-generation therapies for global pharmaceutical and biotechnology partners.
